STAAR Surgical (STAA) Upgraded at Zacks Investment Research

Quantum Capital Management grew its stake in STAAR Surgical by 45.8% during the first quarter. Quantum Capital Management now owns 72,655 …

STAAR Surgical logoZacks Investment Research upgraded shares of STAAR Surgical (NASDAQ:STAA) from a hold rating to a strong-buy rating in a research note published on Tuesday morning, Zacks.com reports. The brokerage currently has $29.00 price target on the medical instruments supplier’s stock.

According to Zacks, “Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. “

Other equities analysts also recently issued reports about the stock. BidaskClub upgraded shares of STAAR Surgical from a hold rating to a buy rating in a research note on Wednesday, February 20th. Canaccord Genuity restated a buy rating and issued a $38.00 price target (down from $43.00) on shares of STAAR Surgical in a research note on Monday. Finally, ValuEngine upgraded shares of STAAR Surgical from a hold rating to a buy rating in a research note on Wednesday, May 1st. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. STAAR Surgical has a consensus rating of Buy and an average price target of $40.33.

Shares of STAA traded down $1.30 during trading hours on Tuesday, hitting $25.96. The company had a trading volume of 27,435 shares, compared to its average volume of 447,169. The firm has a market capitalization of $1.21 billion, a PE ratio of 91.82 and a beta of 2.02. STAAR Surgical has a 12 month low of $21.70 and a 12 month high of $54.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.41 and a quick ratio of 4.83.

STAAR Surgical (NASDAQ:STAA) last issued its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported $0.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.06. The company had revenue of $32.58 million for the quarter, compared to analyst estimates of $32.40 million. STAAR Surgical had a net margin of 4.44% and a return on equity of 13.22%. During the same period in the prior year, the firm earned $0.01 earnings per share. Analysts predict that STAAR Surgical will post 0.33 earnings per share for the current fiscal year.

In other STAAR Surgical news, CTO Keith Holliday sold 2,084 shares of the stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $36.22, for a total transaction of $75,482.48. Following the sale, the chief technology officer now directly owns 40,239 shares in the company, valued at $1,457,456.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Broadwood Partners, L.P. acquired 100,000 shares of STAAR Surgical stock in a transaction on Friday, May 3rd. The shares were purchased at an average price of $22.23 per share, for a total transaction of $2,223,000.00. The disclosure for this purchase can be found here. Insiders sold 17,730 shares of company stock worth $655,538 over the last 90 days. 3.90% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the business. Great West Life Assurance Co. Can grew its stake in STAAR Surgical by 46.8% during the first quarter. Great West Life Assurance Co. Can now owns 5,172 shares of the medical instruments supplier’s stock worth $176,000 after buying an additional 1,649 shares in the last quarter. Cadence Capital Management LLC grew its stake in STAAR Surgical by 66.7% during the first quarter. Cadence Capital Management LLC now owns 113,410 shares of the medical instruments supplier’s stock worth $3,877,000 after buying an additional 45,387 shares in the last quarter. Quantum Capital Management grew its stake in STAAR Surgical by 45.8% during the first quarter. Quantum Capital Management now owns 72,655 shares of the medical instruments supplier’s stock worth $2,484,000 after buying an additional 22,809 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in STAAR Surgical during the first quarter worth about $186,000. Finally, Comerica Bank grew its stake in STAAR Surgical by 7.5% during the first quarter. Comerica Bank now owns 37,197 shares of the medical instruments supplier’s stock worth $1,377,000 after buying an additional 2,600 shares in the last quarter. Hedge funds and other institutional investors own 90.99% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Read More: What is a resistance level?

Get a free copy of the Zacks research report on STAAR Surgical (STAA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for STAAR Surgical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for STAAR Surgical and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

What’s in Store For Juniper Networks, Inc. (NYSE:JNPR) According to Analysts?

Looking further at shares of Juniper Networks, Inc. (NYSE:JNPR), we have noticed that the current consensus target price is $27.82. Wall Street …

Investors may be getting ready to review the most recent company earnings reports. Digging down into the numbers may help provide a good idea of how the company is set up for the foreseeable future. After a recent scan, we can see that the current quarter EPS consensus estimate for Juniper Networks, Inc. (NYSE:JNPR) is 0.4. This EPS estimate is using estimates provided by 11 sell-side analysts polled by Zacks Research. For the previous reporting period, the company posted a quarterly EPS of 0.26. Investors and analysts will be closely watching to see what kind of impact the earnings results have on the stock after the next report.

As company earnings reports continue to roll in, investors will be watching to see which companies hit their numbers for the last reporting period. Investors will also be watching which sectors are reporting the best earnings numbers. A positive overall earnings season could mean that the stock market could keep climbing. Many investors may be cautious with the market trading at current levels. Even though the gloom and doom prognosticators are out in full force, investors have to do the research and decide for themselves which way they believe the market will move in the next couple of months.

Looking further at shares of Juniper Networks, Inc. (NYSE:JNPR), we have noticed that the current consensus target price is $27.82. Wall Street analysts have the ability to create price target estimates for where they think the stock will be moving in the near-term. Because price target projections can differ from one analyst to the next, they may span a wide range of values. Many investors will closely track target prices, and they tend to pay extra close attention when analysts make revisions to those targets.

Just-released reportnames Cannabis Stock of the Year for 2019!Their last pick has seen a +1,200% return since he released it!

This stock has all of the makings of the next great cannabis stock – early-mover advantage, international exposure and influential partnerships, plus it has a product that isunlike anything else on the market…

You will also receive a free, weekly newsletter to stay on top of the latest industry trends, read analysis on promising cannabis stocks, and more.Click here to receive your Free Report immediately!

Wall Street analysts often give buy/sell/hold ratings for the companies that they track. Investors have the ability to view these sell-side ratings in order to help with their own stock research. Analyst ratings may have different interpretations. According to analysts polled by Zacks Research, the current average broker rating on shares of Juniper Networks, Inc. (NYSE:JNPR) is 2.87. This rating uses a scale between 1 and 5. Following this scale, a rating of 1 would represent a Strong Buy, and a rating of 5 would indicate a Strong Sell recommendation. Out of all these analysts offering ratings, 4 have rated the stock a Strong Buy or Buy, according to Zacks Research.

Shifting the focus to some possible support and resistance levels on shares of Juniper Networks, Inc. (NYSE:JNPR), we note that the 52-week high is currently $30.67, and the 52-week low is currently $25.56. When shares are trading near to the 52-week high or 52-week low, investors may be watching for a break through either level. Investors may also be watching historical price action. Over the past 12 weeks, the stock has moved -1.97%. Going back to the start of the year, we can see that shares have moved -1.78%. Over the last 4 weeks, shares have seen a change of -3.93%. Over the last 5 trading days, the stock has moved -5.17%. Checking in on recent session activity, we have seen that the stock has been trading near the $26.43 mark.

When undertaking stock analysis, investors might be searching for companies that are presently undervalued. Undervalued stocks may provide a higher chance of realizing big gains. Finding undervalued stocks that are high quality can be the biggest challenge for the investor. Many investors will dig into the numbers and look for companies that have been consistently making lots of money and performing well on the earnings front.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Is A Downturn Overdue? News Corporation (NWSA), NXP Semiconductors NV (NXPI)?

The shares of News Corporation (NASDAQ:NWSA) has been pegged with a rating of Buy by Citigroup in its latest research note that was published on …

The shares of News Corporation (NASDAQ:NWSA) has been pegged with a rating of Buy by Citigroup in its latest research note that was published on January 14th, 2019. Citigroup wasn’t the only research firm that published a report of News Corporation, with other equities research analysts also giving their opinion on the stock. Goldman advised investors in its research note published on October 9th, 2018, to Buy the NWSA stock. The stock had earned Buy rating from Loop Capital when it published its report on September 4th, 2018. The stock was given Underweight rating by Morgan Stanley in its report released on August 20th, 2018. Loop Capital was of a view that NWSA is Hold in its latest report on March 16th, 2018 while giving it a price target of $17. Rosenblatt thinks that NWSA is worth Buy rating. This was contained in the firm’s report on July 14th, 2017 in which the stock’s price target was also moved to $17.

Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 3 believe it has the potential for further growth, thus rating it as Hold while 1 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $14.33. The price of the stock the last time has raised by 7.32% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 21.27.

The shares of the company added by 0.09% during the trading session on Thursday, reaching a low of $11.22 while ending the day at $11.43. During the trading session, a total of 4.22 million shares were traded which represents a -53.59% decline from the average session volume which is 2.75M shares. NWSA had ended its last session trading at 11.42. News Corporation currently has a market cap of $6.65B while its P/E earnings growth sits at 0.67, with a beta of 1.46. News Corporation debt-to-equity ratio currently stands at 0.18, while its quick ratio hovers at 1.10. NWSA 52-week low price stands at $10.65 while its 52-week high price is $16.65.

The company in its last quarterly report recorded $0.18 earnings per share which is above the $0.14 predicted by most analysts. The News Corporation generated $2,627.00 million in revenue during the last quarter, which is slightly higher than the $2,605.61 million predicted by analysts. In the second quarter last year, the firm recorded $0.17 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 5.56%. News Corporation has the potential to record -2.24 EPS for the current fiscal year, according to equities analysts.

Investment analysts at BofA/Merrill published a research note on May 1st, 2019 where it informed investors and clients that NXP Semiconductors N.V. (NASDAQ:NXPI) is now rated as Buy. Their price target on the stock stands at $125. Goldman also rated NXPI as Upgrade on October 9th, 2018, with its price target of $56 suggesting that NXPI could surge by 3.23% from its current share price. Even though the stock has been trading at $101.50/share, analysts expect it to surge higher by -1.15% to reach $103.68/share. It started the day trading at $100.78 and traded between $96.89 and $100.33 throughout the trading session.

A look at its technical shows that NXPI’s 50-day SMA is 96.40 while its 200-day SMA stands at 87.96. The stock has a high of $122.24 for the year while the low is $67.62. The company’s P/E ratio currently sits at 14.64, while the P/B ratio is 2.80. At the moment, only of NXP Semiconductors N.V. shares were sold short. The company’s average trading volume currently stands at 3.38M shares, which means that the short-interest ratio is just 2.37 days. Over the past seven days, the company moved, with its shift of -5.88%. Looking further, the stock has raised 10.58% over the past 90 days while it gained 21.08% over the last six months.

The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. T Rowe Price Associates Inc bought more NXPI shares, increasing its portfolio by +21.26% during the last quarter. This move now sees T Rowe Price Associates Inc purchasing 4,301,681 shares in the last quarter, thus it now holds 24,537,803 shares of NXPI, with a total valuation of $2,591,682,753. BlackRock Fund Advisors meanwhile bought more NXPI shares in the recently filed quarter, changing its stake to $1,490,628,051 worth of shares. Artisan Partners LP followed the path by increasing its NXPI portfolio by +64.23% in the quarter. This means that Artisan Partners LP bought 4,739,820 shares in the last quarter and now controls 12,119,784 shares of the NXPI stock, with the valuation hitting $1,280,091,586.

Similarly, SSgA Funds Management Inc increased its NXP Semiconductors N.V. shares by +2.36% during the recently filed quarter. After buying 240,480 shares in the last quarter, the firm now controls 10,431,924 shares of NXP Semiconductors N.V. which are valued at $1,101,819,813. In the same vein, Fidelity Management Research Co increased its NXP Semiconductors N.V. shares by during the most recent reported quarter. The firm bought 4,715,863 shares during the quarter which increased its stakes to 10,100,916 shares and is now valued at $1,066,858,748. Following these latest developments, around 86.40% of NXP Semiconductors N.V. stocks are owned by institutional investors and hedge funds.

Related Posts:

  • No Related Posts

Perceptron, Inc. (PRCP) Given $13.00 Consensus Target Price by Brokerages

Several hedge funds and other institutional investors have recently made changes to their positions in PRCP. Quantum Capital Management lifted its …

Perceptron logoPerceptron, Inc. (NASDAQ:PRCP) has received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Analysts have set a 12 month consensus price objective of $13.00 for the company and are predicting that the company will post $0.02 EPS for the current quarter, according to Zacks. Zacks has also assigned Perceptron an industry rank of 198 out of 256 based on the ratings given to its competitors.

Separately, ValuEngine downgraded shares of Perceptron from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st.

Several hedge funds and other institutional investors have recently made changes to their positions in PRCP. Quantum Capital Management lifted its position in Perceptron by 3.1% in the 1st quarter. Quantum Capital Management now owns 142,191 shares of the scientific and technical instruments company’s stock worth $1,066,000 after buying an additional 4,314 shares in the last quarter. Penbrook Management LLC lifted its position in Perceptron by 8.7% in the 1st quarter. Penbrook Management LLC now owns 173,993 shares of the scientific and technical instruments company’s stock worth $1,305,000 after buying an additional 13,950 shares in the last quarter. Vanguard Group Inc lifted its position in Perceptron by 1.1% in the 3rd quarter. Vanguard Group Inc now owns 287,783 shares of the scientific and technical instruments company’s stock worth $2,806,000 after buying an additional 3,100 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in Perceptron by 2.5% in the 3rd quarter. Renaissance Technologies LLC now owns 606,100 shares of the scientific and technical instruments company’s stock worth $5,909,000 after buying an additional 15,000 shares in the last quarter. 70.88% of the stock is owned by institutional investors.

Shares of NASDAQ PRCP opened at $7.16 on Tuesday. Perceptron has a 1-year low of $6.75 and a 1-year high of $12.25. The stock has a market capitalization of $70.21 million, a price-to-earnings ratio of 18.36 and a beta of 0.66. The company has a quick ratio of 1.97, a current ratio of 2.48 and a debt-to-equity ratio of 0.01.

Perceptron (NASDAQ:PRCP) last announced its earnings results on Monday, February 11th. The scientific and technical instruments company reported $0.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.05. Perceptron had a net margin of 4.81% and a return on equity of 7.88%. The company had revenue of $21.55 million during the quarter, compared to the consensus estimate of $19.51 million. On average, equities research analysts anticipate that Perceptron will post 0.45 earnings per share for the current year.

About Perceptron

Perceptron, Inc develops, produces, and sells various automated industrial metrology products and solutions to manufacturing organizations for dimensional gauging, dimensional inspection, and 3D scanning in Europe, Asia, and the Americas. It provides various in-line and near-line measurement solutions, including AutoGauge, AutoGauge ACF, AutoGuide, and Helix evo engineered metrology systems for industrial automated process control and assembly using fixed and robot mounted laser scanners; and offline measurement solutions comprising Coord3 and TouchDMIS for industrial gauging and dimensional inspection using standalone robot mounted laser scanners and coordinate measuring machines.

Read More: Balanced Fund

Get a free copy of the Zacks research report on Perceptron (PRCP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Perceptron Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Perceptron and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

IRIDEX Co. (IRIX) Expected to Announce Earnings of -$0.22 Per Share

Zacks Investment Research’s earnings per share calculations are an … Quantum Capital Management grew its position in shares of IRIDEX by 83.2% …

IRIDEX logoBrokerages expect IRIDEX Co. (NASDAQ:IRIX) to post ($0.22) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for IRIDEX’s earnings. IRIDEX posted earnings per share of ($0.28) during the same quarter last year, which indicates a positive year over year growth rate of 21.4%. The company is expected to report its next quarterly earnings results on Thursday, August 1st.

On average, analysts expect that IRIDEX will report full year earnings of ($0.82) per share for the current year, with EPS estimates ranging from ($0.85) to ($0.79). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.47) per share, with EPS estimates ranging from ($0.50) to ($0.44). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover IRIDEX.

IRIDEX (NASDAQ:IRIX) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.02. The company had revenue of $10.60 million during the quarter, compared to the consensus estimate of $10.46 million. IRIDEX had a negative net margin of 28.06% and a negative return on equity of 42.27%.

IRIX has been the subject of several recent research reports. Roth Capital reissued a “buy” rating on shares of IRIDEX in a research report on Tuesday, February 5th. Zacks Investment Research downgraded shares of IRIDEX from a “hold” rating to a “sell” rating in a research report on Friday, March 8th.

Hedge funds have recently modified their holdings of the business. Gabelli Funds LLC bought a new stake in IRIDEX in the 1st quarter worth about $46,000. Stifel Financial Corp bought a new stake in IRIDEX in the 4th quarter worth about $66,000. Neuberger Berman Group LLC grew its position in shares of IRIDEX by 60.0% during the 3rd quarter. Neuberger Berman Group LLC now owns 24,000 shares of the medical equipment provider’s stock valued at $152,000 after acquiring an additional 9,000 shares during the period. Quantum Capital Management grew its position in shares of IRIDEX by 83.2% during the 4th quarter. Quantum Capital Management now owns 28,829 shares of the medical equipment provider’s stock valued at $135,000 after acquiring an additional 13,089 shares during the period. Finally, FineMark National Bank & Trust grew its position in shares of IRIDEX by 27.5% during the 1st quarter. FineMark National Bank & Trust now owns 39,365 shares of the medical equipment provider’s stock valued at $180,000 after acquiring an additional 8,500 shares during the period. 44.23% of the stock is owned by institutional investors and hedge funds.

NASDAQ:IRIX opened at $5.24 on Tuesday. The stock has a market cap of $69.53 million, a PE ratio of -4.99 and a beta of 1.05. IRIDEX has a one year low of $3.72 and a one year high of $9.48.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.

Featured Story: Bar Chart

Get a free copy of the Zacks research report on IRIDEX (IRIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IRIDEX Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for IRIDEX and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts